Oncternal Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Oncternal Therapeutics

05/11/2021 06:47

* Oncternal Therapeutics Inc  ONCT.OQ  reported a quarterly
adjusted loss of 19 cents​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for a loss of 16 cents per share.
* Revenue rose 263.8% to $2.13 million from a year ago; 
analysts expected $1.30 million. 
* Oncternal Therapeutics Inc's reported EPS for the quarter was
a loss of 19 cents​.
* The mean earnings estimate of analysts was unchanged in the
last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Oncternal Therapeutics Inc shares had fallen by 2.4% this
quarter and lost 16.9% so far this year.
* The company reported a quarterly loss of $9.63 million.
* Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $16.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 5 at 06:47 a.m.
 ​All figures in US dollars unless otherwise stated